Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

Journal of Clinical Oncology

Volumn 27, Issue 20, 2009, Pages 3297-3302

  Jiralerspong, Sao ^a   Palla, Shana L ^a   Giordano, Sharon H ^a   Meric Bernstam, Funda ^a   Liedtke, Cornelia ^a   Barnett, Chad M ^a   Hsu, Limin ^a   Hung, Mien Chie ^a   Hortobagyi, Gabriel N ^a   Gonzalez Angulo, Ana M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; INSULIN; METFORMIN; PACLITAXEL; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT RESPONSE; ADJUVANT THERAPY; BREAST TUMOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; REMISSION; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; METFORMIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67749144226     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.19.6410     Document Type: Article

References (41)

1. Rastogi P, Anderson SJ, Bear HD, et al: Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778-785, 2008
2. Mieog JS, van der Hage JA, van de Velde CJ: Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2:CD005002, 2007
3. Wolf I, Sadetzki S, Catane R, et al: Diabetes mellitus and breast cancer. Lancet Oncol 6:103-111, 2005
4. Xue F, Michels KB: Diabetes, metabolic syndrome, and breast cancer: A review of the current evidence. Am J Clin Nutr 86:s823-s835, 2007
5. Larsson SC, Mantzoros CS, Wolk A: Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer 121:856-862, 2007
6. Yancik R, Wesley MN, Ries LA, et al: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285: 885-892, 2001
7. Verlato G, Zoppini G, Bonora E, et al: Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 26:1047-1051, 2003
8. Coughlin SS, Calle EE, Teras LR, et al: Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160-1167, 2004
9. Renehan AG, Tyson M, Egger M, et al: Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 371:569-578, 2008
10. Carmichael AR: Obesity and prognosis of breast cancer. Obes Rev 7:333-340, 2006
11. Calle EE, Rodriguez C, Walker-Thurmond K, et al: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625-1638, 2003
12. Goodwin PJ: Insulin in the adjuvant breast cancer setting: A novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol 26:833-834, 2008
13. Calle EE, Kaaks R: Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579-591, 2004
14. Renehan AG, Frystyk J, Flyvbjerg A: Obesity and cancer risk: The role of the insulin-IGF axis. Trends Endocrinol Metab 17:328-336, 2006
15. Pollak MN, Schernhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-518, 2004
16. Yee D: Targeting insulin-like growth factor pathways. Br J Cancer 94:465-468, 2006
17. Evans JM, Donnelly LA, Emslie-Smith AM, et al: Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305, 2005
18. Bowker SL, Majumdar SR, Veugelers P, et al: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254-258, 2006
19. Zakikhani M, Dowling R, Fantus IG, et al: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-10273, 2006
20. Dowling RJ, Zakikhani M, Fantus IG, et al: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67:10804-10812, 2007
21. Ben Sahra I, Laurent K, Loubat A, et al: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27:3576-3586, 2008
22. Buzzai M, Jones RG, Amaravadi RK, et al: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745-6752, 2007
23. Huang X, Wullschleger S, Shpiro N, et al: Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 412:211-221, 2008
24. Anisimov VN, Berstein LM, Egormin PA, et al: Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 40:685-693, 2005
25. Guarneri V, Broglio K, Kau SW, et al: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037-1044, 2006
26. Galli A, Mello T, Ceni E, et al: The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin Investig Drugs 15:1039-1049, 2006
27. Muoio DM, Newgard CB: Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 9:193-205, 2008
28. Pollak MN, Chapman JW, Shepherd L, et al: Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. J Clin Oncol 24:9s, 2006 (suppl; abstr 524)
29. Goodwin PJ, Ennis M, Pritchard KI, et al: Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J Clin Oncol 20:42-51, 2002
30. Pasanisi P, Berrino F, De Petris M, et al: Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119:236-238, 2006
31. Goodwin PJ, Pritchard KI, Ennis M, et al: Metformin lowers fasting insulin levels in nondiabetic hyperinsulinemic early stage breast cancer patients. Breast Cancer Res Treat 100:S109, 2006
32. Ligibel JA, Campbell N, Partridge A, et al: Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol 26:907-912, 2008
33. Chlebowski RT, Blackburn GL, Thomson CA, et al: Dietary fat reduction and breast cancer outcome: Interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 98:1767-1776, 2006
34. Chlebowski RT, Blackburn GL, Hoy MK, et al: Survival analyses from the Women's Intervention Nutrition Study (WINS) evaluating dietary fat reduction and breast cancer outcome. J Clin Oncol 26: 12s, 2008 (suppl; abstr 522)
35. Fairey AS, Courneya KS, Field CJ, et al: Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: A randomized controlled trial. Cancer Epidemiol Biomarkers Prev 12:721-727, 2003
36. Schmitz KH, Ahmed RL, Hannan PJ, et al: Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomarkers Prev 14:1672-1680, 2005
37. Shaw RJ, Lamia KA, Vasquez D, et al: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642-1646, 2005
38. Corradetti MN, Inoki K, Bardeesy N, et al: Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 18: 1533-1538, 2004
39. Inoki K, Zhu T, Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-590, 2003
40. Shaw RJ, Bardeesy N, Manning BD, et al: The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:91-99, 2004
41. Gralow JR, Burstein HJ, Wood W, et al: Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26:814-819, 2008